producing ST25 A. baumannii in pets. Our findings expand recent data on two isolates recovered from healthy dogs in the region of Nantes (11) and highlight an emerging and worrying epidemiological picture, with a possible endemicity of OXA-23-producing ST25 A. baumannii in pets in France.
So far, OXA-23-producing A. baumannii isolates from animals have belonged to ST2 (3, 4, 12) , suggesting cross-transmission of such isolates from humans to animals (4) . Looking at human clinics in France, OXA-23-producing ST2 A. baumannii is the predominant clone (2, 13). However, Jeannot et al. have also reported the occurrence of ST25 A. baumannii among human isolates, albeit mostly harboring OXA-58 (2). Our results suggest that the epidemiology of carbapenem-resistant A. baumannii in companion animals might be independent of that in humans. Nonetheless, incidental transmission of OXA-23-producing ST25 A. baumannii from humans to pets cannot be excluded, even though the process that might favor the persistence and circulation of this clone among different individuals remains to be elucidated. On the other hand, carbapenems do not belong to the therapeutic arsenal used in veterinary medicine but penicillins or penicillin-␤-lactamase inhibitor combinations might select for OXA-23-producing A. baumannii. Moreover, many other veterinary antibiotics can coselect intrinsic resistances of A. baumannii and contribute to a further clonal spread. In light of the remarkable prevalence of ST25 A. baumannii associated with urinary tract infections in our study, a possible special tropism of such a clone as a uropathogen needs further evaluation. These findings make it urgent to investigate the processes favoring the emergence and spread of OXA-producing A. baumannii in veterinary settings. CAZ, ceftazidime (S, Ն18; R, Ͻ15); FEP, cefepime (S, Ն18; R, Ͻ15); TOB, tobramycin (S, Ն17; R, Ͻ17); GN, gentamicin (S, Ն17; R, Ͻ17); AK, amikacin (S, Ն18; R, Ͻ15); NET, netilmicin (S, Ն16; R, Ͻ16); CIP, ciprofloxacin (S, Ն21; R, Ͻ21); SXT, trimethoprim-sulfamethoxazole (S, Ն16; R, Ͻ13). c Cloxacillin (CLO) was added to the medium at a concentration of 250 g/ml to unveil the hydrolytic mechanism responsible for ␤-lactam resistance.
